Induction of labour in case of premature rupture of membranes at term with an unfavourable cervix: protocol for a randomised controlled trial comparing double balloon catheter (+oxytocin) and vaginal prostaglandin (RUBAPRO) treatments.
Administration, Intravaginal
Catheters
Cervical Ripening
Cervix Uteri
Delayed-Action Preparations
/ administration & dosage
Delivery, Obstetric
Female
Fetal Membranes, Premature Rupture
France
Humans
Labor, Induced
/ methods
Oxytocics
/ administration & dosage
Oxytocin
/ administration & dosage
Parity
Pregnancy
Prospective Studies
Prostaglandins
/ administration & dosage
Randomized Controlled Trials as Topic
cervical ripening balloon
labor induction
pharmacological cervical maturation
premature rupture of membranes
unfavorable cervix
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
20 06 2019
20 06 2019
Historique:
entrez:
23
6
2019
pubmed:
23
6
2019
medline:
2
7
2020
Statut:
epublish
Résumé
Premature rupture of membranes (PROM) occurs at term in 8% of pregnancies. Several studies have demonstrated that the risk of chorioamnionitis and neonatal sepsis increases with duration of PROM. Decreasing the time interval between PROM and delivery is associated with lower rates of maternal infections. In case of an unfavourable cervix, the use of prostaglandin for cervical maturation demonstrates some advantages over oxytocin. The use of double balloon catheter in reduction of PROM duration has not been evaluated in the literature. We are conducting a prospective, monocentric, randomised clinical trial on pregnant women with an unfavourable cervix showing PROM at term (RUBAPRO).After 12-24 hours of PROM, women are randomly assigned to one group treated with a double balloon catheter for 12 hours, with oxytocin administered after 6 hours or to the control group treated with 24 hours of vaginal prostaglandin followed by oxytocin infusion alone. Patients (n=80) are randomised at a 1:1 ratio with stratification on parity.The inclusion criteria are a Bishop score of <6, cephalic presentation at term and confirmed PROM. Women with suspected chorioamnionitis; group B streptococcus (GBS) carrier; a history of caesarean delivery or any contraindication for vaginal delivery are excluded.The time from induction to delivery is the primary outcome. Secondary outcomes were mode of delivery, maternofetal morbidity and the effect of parity on strategies for reduction of PROM duration.To sufficiently demonstrate a difference (10 hours) between groups-with a statistical power of 90% and a two-tailed α of 5%-40 patients per group will be required. Written informed consent is required from participants.National Ethics Committee approval was obtained in August 2017. The results will be published in a peer-reviewed journal and presented at relevant conferences. Access to raw data will be available only to members of the research team. NCT03310333.
Identifiants
pubmed: 31227530
pii: bmjopen-2018-026090
doi: 10.1136/bmjopen-2018-026090
pmc: PMC6596956
doi:
Substances chimiques
Delayed-Action Preparations
0
Oxytocics
0
Prostaglandins
0
Oxytocin
50-56-6
Banques de données
ClinicalTrials.gov
['NCT03310333']
Types de publication
Clinical Trial Protocol
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e026090Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cochrane Database Syst Rev. 2014 Jun 19;(6):CD003101
pubmed: 24941907
Am J Obstet Gynecol. 2017 Sep;217(3):360.e1-360.e7
pubmed: 28479288
Int J Gynaecol Obstet. 2015 Oct;131(1):13-24
pubmed: 26433401
Am J Perinatol. 2016 Jul;33(9):866-72
pubmed: 27031055
Obstet Gynecol. 2015 Sep;126(3):539-51
pubmed: 26244535
J Obstet Gynaecol Res. 2018 Jan;44(1):27-34
pubmed: 29271034
Am J Obstet Gynecol. 1970 Feb 1;106(3):469-83
pubmed: 4905833
N Engl J Med. 1996 Apr 18;334(16):1005-10
pubmed: 8598837
Am J Obstet Gynecol. 2010 Nov;203(5):418-29
pubmed: 20605133
Cochrane Database Syst Rev. 2000;(2):CD000159
pubmed: 10796161
Am J Obstet Gynecol. 1997 Nov;177(5):1024-9
pubmed: 9396886
J Am Osteopath Assoc. 2014 Sep;114(9):686-92
pubmed: 25170038
Gynecol Obstet Fertil Senol. 2017 Jun;45(6):348-352
pubmed: 28552753
Obstet Gynecol. 2018 Jan;131(1):4-11
pubmed: 29215519
Gynecol Obstet Invest. 1998;46(1):1-4
pubmed: 9692332
Arch Gynecol Obstet. 2018 May;297(5):1089-1100
pubmed: 29445926
J Matern Fetal Neonatal Med. 2016 Mar;29(6):967-71
pubmed: 25845274
Cochrane Database Syst Rev. 2017 Jan 04;1:CD005302
pubmed: 28050900
Obstet Gynecol. 2009 Aug;114(2 Pt 1):386-97
pubmed: 19623003